Pursuant to the requirements of Section 13 or 15(d) Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized
| CNS PHARMACEUTICALS, INC. | |
| Date: April 1, 2024 | By: | /s/ John Climaco |
|---|
| John Climaco |
| Chief Executive Officer and Director (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacity and on the dates indicated.
| Date: April 1, 2024 | By: | /s/ John Climaco |
|---|
| John Climaco |
| Chief Executive Officer, President and Director (Principal Executive Officer) |
| Date: April 1, 2024 | /s/ Christopher Downs |
|---|
| Christopher Downs |
| Chief Financial Officer (Principal Financial and Accounting Officer) |
| Date: April 1, 2024 | /s/ Faith Charles |
|---|
| Faith Charles |
| Director |
| Date: April 1, 2024 | /s/ Jerzy (George) Gumulka |
|---|
| Jerzy (George) Gumulka |
| Director |
| Date: April 1, 2024 | /s/ Carl Evans |
|---|
| Carl Evans |
| Director |
| Date:April 1, 2024 | /s/ Jeffry Keyes |
|---|
| Jeffry Keyes |
| Director |
| Date: April 1, 2024 | /s/ Bettina Cockroft |
|---|
| Bettina Cockroft |
| Director |
| Date: April 1, 2024 | /s/ Amy Mahery |
|---|
| Amy Mahery |
| Director |
